EpiBiologics Revenue and Competitors
Estimated Revenue & Valuation
- EpiBiologics's estimated annual revenue is currently $2.6M per year.
- EpiBiologics's estimated revenue per employee is $65,577
- EpiBiologics's total funding is $73M.
Employee Data
- EpiBiologics has 39 Employees.
- EpiBiologics grew their employee count by 34% last year.
EpiBiologics's People
| Name | Title | Email/Phone |
|---|
EpiBiologics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 5 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 4 | -50% | N/A | N/A |
#6 | $0.7M | 8 | 0% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 17 | 31% | N/A | N/A |
What Is EpiBiologics?
EpiBiologics is building a next-generation protein degradation platform that targets membrane and extracellular proteins. EpiBiologics was founded in 2022 based on the pioneering work from academic founder Dr. Jim Wells of the University of California San Francisco (UCSF). The Company’s proprietary EpiTAC platform is a modular antibody-based system that enables the precise degradation of disease-driving membrane and extracellular proteins in a tissue-specific manner. Headquartered in San Mateo, EpiBiologics is backed by leading healthcare investors and aims to develop first-in-class and best-in-class targeted therapies across multiple therapeutic areas. For more information, please visit epibiologics.com and follow us on LinkedIn.
keywords:N/A
$73M
Total Funding
39
Number of Employees
$2.6M
Revenue (est)
34%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in San Mateo
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $15M | 39 | 11% | N/A |
#2 | $5.8M | 39 | 0% | N/A |
#3 | $7.6M | 39 | 5% | N/A |
#4 | $11.6M | 40 | 21% | N/A |
#5 | $4.5M | 40 | 14% | N/A |